Suppr超能文献

替代终点分析与内生性之间的联系。

Links between analysis of surrogate endpoints and endogeneity.

机构信息

Department of Statistics, Penn State University, University Park, PA, USA.

出版信息

Stat Med. 2010 Dec 10;29(28):2869-79. doi: 10.1002/sim.4027.

Abstract

There has been substantive interest in the assessment of surrogate endpoints in medical research. These are measures that could potentially replace 'true' endpoints in clinical trials and lead to studies that require less follow-up. Recent research in the area has focused on assessments using causal inference frameworks. Beginning with a simple model for associating the surrogate and true endpoints in the population, we approach the problem as one of endogenous covariates. An instrumental variables estimator and general two-stage algorithm are proposed. Existing surrogacy frameworks are then evaluated in the context of the model. In addition, we define an extended relative effect estimator as well as a sensitivity analysis for assessing what we term the treatment instrumentality assumption. A numerical example is used to illustrate the methodology.

摘要

人们对替代终点评估在医学研究中的应用产生了浓厚的兴趣。这些替代终点是指在临床试验中可能替代“真实”终点的指标,可以减少研究所需的随访时间。该领域最近的研究集中在使用因果推理框架进行评估上。从关联人群中替代终点和真实终点的简单模型开始,我们将问题视为内源性协变量问题。我们提出了一种工具变量估计量和一般两阶段算法。然后,我们在模型的背景下评估现有的替代终点框架。此外,我们定义了一个扩展的相对效应估计量以及敏感性分析,用于评估我们所谓的治疗工具性假设。通过一个数值例子来说明该方法。

相似文献

1
Links between analysis of surrogate endpoints and endogeneity.
Stat Med. 2010 Dec 10;29(28):2869-79. doi: 10.1002/sim.4027.
3
An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference.
Biometrics. 2016 Sep;72(3):669-77. doi: 10.1111/biom.12483. Epub 2016 Feb 10.
4
A reflection on the possibility of finding a good surrogate.
J Biopharm Stat. 2019;29(3):468-477. doi: 10.1080/10543406.2018.1559854. Epub 2019 Jan 26.
5
A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
Stat Med. 2014 Aug 30;33(19):3338-53. doi: 10.1002/sim.6180. Epub 2014 Apr 29.
6
Methods for the analysis of multiple endpoints in small populations: A review.
J Biopharm Stat. 2019;29(1):1-29. doi: 10.1080/10543406.2018.1489402. Epub 2018 Jul 9.
7
Novel procedures for validating surrogate endpoints in clinical trials.
Curr Clin Pharmacol. 2007 May;2(2):123-8. doi: 10.2174/157488407780598126.
8
A reflection on the causal interpretation of individual-level surrogacy.
J Biopharm Stat. 2019;29(3):529-540. doi: 10.1080/10543406.2019.1579221. Epub 2019 Feb 16.
9
Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity.
Stat Methods Med Res. 2024 Jul;33(7):1152-1162. doi: 10.1177/09622802241247719. Epub 2024 May 8.
10
A comparative study of matched pair designs with two binary endpoints.
Stat Methods Med Res. 2017 Dec;26(6):2526-2542. doi: 10.1177/0962280215601136. Epub 2016 Jul 11.

引用本文的文献

2
Assessing mediation using marginal structural models in the presence of confounding and moderation.
Psychol Methods. 2012 Dec;17(4):642-64. doi: 10.1037/a0029311. Epub 2012 Aug 20.
3
A causal framework for surrogate endpoints with semi-competing risks data.
Stat Probab Lett. 2012 Oct;82(11):1898-1902. doi: 10.1016/j.spl.2012.06.010. Epub 2012 Jun 16.
4
Rejoinder for "Meta-analysis for surrogacy: accelerated failure time models and semi-competing risks modelling".
Biometrics. 2012 Mar;68(1):245-247. doi: 10.1111/j.1541-0420.2011.01638.x. Epub 2011 Jun 13.
5
A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.
Biostatistics. 2012 Sep;13(4):609-24. doi: 10.1093/biostatistics/kxs003. Epub 2012 Mar 6.

本文引用的文献

1
Extended instrumental variables estimation for overall effects.
Int J Biostat. 2008 Apr 7;4(1):Article 4. doi: 10.2202/1557-4679.1082.
2
A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
Biometrics. 2010 Jun;66(2):523-31. doi: 10.1111/j.1541-0420.2009.01303.x. Epub 2009 Aug 10.
3
Related causal frameworks for surrogate outcomes.
Biometrics. 2009 Jun;65(2):530-8. doi: 10.1111/j.1541-0420.2008.01106.x.
4
Evaluating candidate principal surrogate endpoints.
Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.
5
Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling.
J Health Econ. 2008 May;27(3):531-43. doi: 10.1016/j.jhealeco.2007.09.009. Epub 2007 Dec 4.
7
Counterfactual links to the proportion of treatment effect explained by a surrogate marker.
Biometrics. 2005 Dec;61(4):1102-11. doi: 10.1111/j.1541-0420.2005.00380.x.
8
Estimating probit models with self-selected treatments.
Stat Med. 2006 Feb 15;25(3):389-413. doi: 10.1002/sim.2226.
9
Does the Prentice criterion validate surrogate endpoints?
Stat Med. 2004 May 30;23(10):1571-8. doi: 10.1002/sim.1780.
10
The validation of surrogate endpoints in meta-analyses of randomized experiments.
Biostatistics. 2000 Mar;1(1):49-67. doi: 10.1093/biostatistics/1.1.49.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验